Cumberland Pharmaceuticals — Q3 2026 Earnings Summary

Financial Performance:

• Net income for the quarter ended September 30, 2026, was $77.8 million, driven by an $81.1 million gain on the disposal of discontinued operations (Strategic Transaction with Apotex Health).
• Total revenue for the quarter was $2.2 million, consisting of $1.95 million in transition services revenue and $206,356 in net revenue, compared to $171,821 in the prior year quarter.
• Net loss from continuing operations was $1.1 million for the quarter, compared to a loss of $2.7 million in the prior year quarter.
• For the nine months ended September 30, 2026, net income was $70.2 million, compared to a net loss of $1.4 million in the prior year period.
• Total revenue for the nine months ended September 30, 2026, was $2.5 million, compared to $719,247 in the prior year period.
• Cash and cash equivalents increased to $80.6 million at September 30, 2026, from $11.4 million at December 31, 2025.
• Total assets were $113.8 million at September 30, 2026, compared to $76.8 million at December 31, 2025.
• Total liabilities were $41.6 million at September 30, 2026, compared to $52.3 million at December 31, 2025.
• Shareholders' equity increased to $72.5 million at September 30, 2026, from $24.9 million at December 31, 2025.
• Operating cash flow from continuing operations for the nine months ended September 30, 2026, was a use of $1.1 million, compared to a use of $2.5 million in the prior year period.
• Investing cash flow from continuing operations for the nine months ended September 30, 2026, was a use of $1.9 million, compared to a use of $679,577 in the prior year period.
• Financing cash flow for the nine months ended September 30, 2026, was a use of $28.0 million, primarily due to payments on the line of credit ($5.2 million) and cash dividends paid ($22.5 million).

Guidance and Future Outlook:

• Cumberland plans to submit a New Drug Application (NDA) to the FDA for ifetroban as a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
• The FDA has granted a rolling review for the NDA submission.
• The company intends to seek approval based on Phase 2 FIGHT DMD trial data and natural history data without conducting additional trials, subject to FDA agreement.
• Top-line results from the Phase 2a ASSIST-SSc trial in Systemic Sclerosis will inform future development decisions for ifetroban in this indication.
• The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.

Business Segments and Product Lines:

• The company has transitioned to a development-focused model following the July 1, 2026, closing of its Strategic Transaction with Apotex Health, which integrated Cumberland's commercial brands into Apotex's U.S. branded business.
• The primary focus is now on the clinical pipeline led by ifetroban.
• Ifetroban is being evaluated in Phase 2 programs for Idiopathic Pulmonary Fibrosis and Cancer Metastasis.
• Ifetroban has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations for the DMD heart disease indication.
• The FDA has conditionally accepted "DYSCORBAN" as the proprietary name for ifetroban.
• Cumberland has secured a growing portfolio of patents protecting ifetroban for the DMD heart disease indication.

Market and Competitive Landscape:

• There is currently no approved therapy specifically targeting DMD heart disease, which is the leading cause of death in these patients.
• Systemic Sclerosis (SSc) is characterized by diffuse fibrosis of the skin and internal organs with no approved therapy for the underlying condition.
• The company operates in the rare disease biopharmaceutical sector, focusing on unmet medical needs.

Risks and Challenges:

• The FDA may refuse to file the NDA or may not approve ifetroban.
• The FDA may not agree with the company's interpretation of meeting outcomes or may require additional trials and data, potentially delaying approval and requiring substantial additional capital.
• Additional data from ongoing studies may not be favorable.
• The company must meet FDA approval requirements, including chemistry, manufacturing, and controls requirements.
• The rolling review process may not shorten the review timeline.
• Restrictions may be placed on the product label if approved.
• Changes in FDA requirements, policies, or regulatory pathways could impact the business.
• The company faces risks related to competition, reliance on third parties, and market acceptance.

Management Commentary and Tone:

• CEO A.J. Kazimi stated that the first full quarter as a development-focused company reinforced the value of concentrating efforts on the clinical pipeline.
• Management expressed confidence in the company's financial strength and expertise to pursue the new mission of developing medicines for unmet medical needs.
• The company has adopted a refined mission statement emphasizing innovation and advancing new therapies for significant unmet medical needs.

Other Key Points:

• The Strategic Transaction with Apotex Health closed on July 1, 2026, generating $100 million in proceeds at closing.
• The transaction simplified the business model and allowed the company to concentrate resources on its clinical pipeline.
• The Phase 2 FIGHT DMD trial demonstrated a statistically significant 5.4 percentage point improvement in left ventricular ejection fraction in the high-dose group compared to controls.
• Ifetroban has maintained a favorable safety profile in DMD patients through up to 36 months of treatment, with no treatment-related serious adverse events.
• The safety database for ifetroban includes more than 1,400 subjects across approximately 30 clinical studies.
• The company paid cash dividends of $22.5 million during the nine months ended September 30, 2026.
• The company paid $318,820 for repurchases of common shares during the nine months ended September 30, 2026.
• The company paid $5.2 million on its revolving line of credit during the nine months ended September 30, 2026.